herpes zoster
Conditions
Interventions
Conventional drug treatment + UVA1 treatment group:ultraviolet (UVA1) phototherapy + conventional medical treatment
Conventional drug treatment group:conventional medical treatment
Sponsors
The First Affiliated Hospital of Army Medical University, PLA
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Aged over 18 years; 2. The clinical diagnosis of herpes zoster is clearly based on its trigger, disease development process, skin lesion manifestations and symptoms. Within 3 days of the occurrence of erythema and blisters, the symptoms are moderate and severe: the skin lesion area accounts for more than 1% of the body surface area, and the VAS pain score is more than 6 points; 3. The patients had good compliance with the planned treatment, understood the research process of this study and signed written informed consent; 4. Volunteer to participate in this study and be willing to randomly receive one of the two treatment modalities.
Exclusion criteria
Exclusion criteria: 1. Accompanied by other types of local pain and discomfort, pain symptoms induced by other systemic diseases, or secondary infection, ulcer or other skin lesions affecting the judgment of treatment effect in the skin area involved by herpes zoster; 2. Patients with severe infections, malignant tumors, lupus erythematosus, dermatomyositis, xeroderma pigmentosus, porphyria, photosensitive skin diseases (such as pleomorphic solar rash, chronic photochemical dermatitis, solar urticaria, etc.), cataract and other diseases; Patients with a history of skin melanoma and non-melanoma; 3. Patients with diabetes mellitus, severe cardiac insufficiency, severe hepatic and renal insufficiency or other serious diseases; 4. Has taken vitamin A acid, hydroxychloroquine sulfate, doxycycline and minocycline hydrochloride, sulfa antibiotics (such as compound new Ming), thiazide antihypertensive drugs (such as hydrochlorothiazide), quinolones (e.g., levofloxacin), phenothiazine antipsychotic drugs (e.g., chlorpromazine), sensitizer scurfpea fruit grain, griseofulvin antifungal agents and voriconazole photosensitive drugs in a nearly month; 5. Patients with a history of photochemotherapy within the past 1 month; 6. Pregnant and lactating women and patients of childbearing age who refused to take appropriate contraceptive measures during the trial; 7. Alcoholics, drug addicts and abnormal spirits; 8. Patients judged by the investigator to be unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of blister scabbing (BsT);Erythema resolution time (EeT);Pain Visual analogue scale (VAS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory biomarkers;Dermatology Quality of Life Score (DLQI);Patient's analgesic consumption; | — |
Countries
China
Contacts
Public ContactQiquan Chen
The First Affiliated Hospital of Army Medical University, PLA
Outcome results
None listed